论文信息 - Once‐weekly (70 mg/m2) vs twice‐weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials - 字舞流文

Once‐weekly (70 mg/m2) vs twice‐weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials

M. Dimopoulos | D. Siegel | R. Orlowski | N. Raje | P. Moreau | T. Facon | J. Berenson | M. Mateos | Haijun Ma | Hui Yang | K. Iskander | A. Zahlten-Kumeli | J. Berdeja | Z. Klippel | Khalid Mezzi | K. Stewart | Zandra K. Klippel